Version 1
: Received: 2 October 2024 / Approved: 3 October 2024 / Online: 4 October 2024 (08:14:47 CEST)
How to cite:
León Fernández, O. S.; Oru, G. T.; Viebahn-Haensler, R.; López Cabreja, G.; Serrano Espinosa, I.; Corrales Vázquez, M. E. Medical Ozone. Redox Regulation and a New Mechanism in the Treatment of Rheumatoid Arthritis. Preprints2024, 2024100288. https://doi.org/10.20944/preprints202410.0288.v1
León Fernández, O. S.; Oru, G. T.; Viebahn-Haensler, R.; López Cabreja, G.; Serrano Espinosa, I.; Corrales Vázquez, M. E. Medical Ozone. Redox Regulation and a New Mechanism in the Treatment of Rheumatoid Arthritis. Preprints 2024, 2024100288. https://doi.org/10.20944/preprints202410.0288.v1
León Fernández, O. S.; Oru, G. T.; Viebahn-Haensler, R.; López Cabreja, G.; Serrano Espinosa, I.; Corrales Vázquez, M. E. Medical Ozone. Redox Regulation and a New Mechanism in the Treatment of Rheumatoid Arthritis. Preprints2024, 2024100288. https://doi.org/10.20944/preprints202410.0288.v1
APA Style
León Fernández, O. S., Oru, G. T., Viebahn-Haensler, R., López Cabreja, G., Serrano Espinosa, I., & Corrales Vázquez, M. E. (2024). Medical Ozone. Redox Regulation and a New Mechanism in the Treatment of Rheumatoid Arthritis. Preprints. https://doi.org/10.20944/preprints202410.0288.v1
Chicago/Turabian Style
León Fernández, O. S., Irainis Serrano Espinosa and María Elena Corrales Vázquez. 2024 "Medical Ozone. Redox Regulation and a New Mechanism in the Treatment of Rheumatoid Arthritis" Preprints. https://doi.org/10.20944/preprints202410.0288.v1
Abstract
Medical ozone is a redox regulator with beneficial effects in oxidative etiology diseases such as rheumatoid arthritis (RA). The aim of this study was to conduct a holistic review from different pharmacological trials involving ozone in model diseases as well as the clinical response of RA patients. The ROS involved in RA and its relationship to the main pathological pathways of this autoimmune disease were here considered. The integrator analysis of experimental results from animals with clinical findings have revealed that both methotrexate (MTX) and medical ozone share common mechanisms via adenosinergic regulation. This finding has enabled us to propose a new pharmacological mechanism in the treatment of RA. We concluded that MTX + medical ozone combined therapy reduces ROS overproduction and the generation of proinflammatory cytokines, and decreases anti-cyclic citrullinate peptide levels by a mutual mechanism involving adenosine A1 receptors.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
